HIGHLIGHTS
- who: M. Cebey-Lu00f3pez et al. from the (UNIVERSITY) have published the research work: Case Report: Everolimus reduced bone turnover markers but showed no clinical benefit in a patient with severe progressive osseous heteroplasia, in the Journal: (JOURNAL)
SUMMARY
Progressive osseous heteroplasia (POH) is an ultrarare genetic condition that manifests as progressive extra-skeletal bone formation, usually in early life. POH is clinically characterized by a progressive heterotopic bone formation within the dermis and subcutaneous adipose_tissue that progresses to deep connective tissue, including fascia, skeletal muscle, tendon, and ligament. Over time, POH dermal . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.